Factors to Influence Archer Daniels (ADM) This Earnings Season
Archer Daniels Midland Company ADM is slated to report fourth-quarter 2021 results on Jan 25, before market open. The leading agricultural product company is likely to have witnessed earnings and revenue growth in the to-be-reported quarter.
The Zacks Consensus Estimate for the company’s fourth-quarter earnings is pegged at $1.36 per share, which suggests an increase of 12.4% from the year-ago quarter’s reported figure. The consensus mark has moved up 8.8% in the past seven days. For fourth-quarter revenues, the consensus mark is pegged at $20.4 billion, suggesting 13.3% growth from the prior-year quarter’s reported figure.
In the last reported quarter, the company delivered an earnings surprise of 6.6%. Its earnings outperformed the Zacks Consensus Estimate by 23.4% on average, in the trailing four quarters.
Archer Daniels Midland Company Price and EPS Surprise
Key Factors to Note
Archer Daniels has been gaining from solid demand and continued growth in the Nutrition segment. Significant gains in the Human and Animal Nutrition units have been aiding the Nutrition business. The trends are expected to have continued in the fourth quarter.
Within the Human Nutrition unit, the North America and EMEA regions have been benefiting from the strength in the flavors business, stemming from higher volumes and better product mix, particularly in the beverage category. Sales growth in alternative proteins is likely to have aided the Specialty Ingredients unit. In contrast, robust sales in bioactives and fiber are expected to have contributed to the Health & Wellness category.
The Animal Nutrition unit is expected to have witnessed continued positive demand in amino acids, and strength in feed additives and ingredients. The company’s recent buyouts and joint ventures are expected to have leveraged the rising demand for pet food, sustainable fuel and plant-based products, in turn, aiding the fourth-quarter performance.
The company has been making efforts to expand its solutions portfolio, which forms part of its Carbohydrate Solutions unit. Such endeavors are expected to have aided the company’s top line in the quarter under review.
However, Archer Daniels remains exposed to headwinds, including higher performance-related compensation, project-related costs, and the shifting of costs from business segments into the centralized centers of excellence in the supply chain and operations.
On its last reported quarter’s earnings call, management warned about higher manufacturing costs in the Carbohydrates Solutions and Ag Services & Oilseeds segments in the fourth quarter of 2021.
What the Zacks Model Unveils
Our proven model conclusively predicts an earnings beat for Archer Daniels this time around. The combination of a positive
Archer Daniels has a Zacks Rank #3 and an Earnings ESP of +2.88%.
Other Stocks With Favorable Combination
Here are some more companies you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season:
Hormel Foods
Hormel Foods’ top line is expected to rise year over year. The Zacks Consensus Estimate for quarterly revenues is pegged at $2.95 billion, which suggests a rise of 19.8% from the figure reported in the prior-year quarter. HRL has delivered an earnings beat of 1.8%, on average, in the trailing four quarters.
Beyond Meat
However, Beyond Meat’s top line is expected to rise year over year. The Zacks Consensus Estimate for BYND’s quarterly revenues is pegged at $104 million, which suggests a rise of 2% from the figure reported in the prior-year quarter.
Hershey
Hershey’s top line is also expected to rise year over year. The Zacks Consensus Estimate for quarterly revenues is pegged at $2.2 billion, which suggests a rise of 2.6% from the figure reported in the prior-year quarter. HSY has delivered an earnings beat of 4.4%, on average, in the trailing four quarters.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
As one investor put it, “curing and preventing hundreds of diseases…what should that market be worth?” This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.